Cellectar to seek approval for radioactive iodine-based therapy in rare blood cancer
Cellectar Biosciences reported Tuesday that 80% of patients with a rare blood cancer evaluated in a pivotal study responded to the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
